Abstracts tagged "Myocardial Infarction"

Abstract Number: 0174 • ACR Convergence 2024
A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Omair Khan¹, Kundan Jana², Azka Naeem², Syed Mujtaba Baqir², Marlon Rivera Boadla², Muhammad Hashim khan² and Vijay Shetty², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune condition characterized by widespread skin fibrosis and/or end-organ damage. Previous studies have reported variable outcomes of the disease…
Abstract Number: 1981 • ACR Convergence 2024
Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
Manush Sondhi¹, Samina Hayat², Kinza Muzaffar¹ and Sarwat Umer¹, ¹LSU HEALTH SHREVEPORT, Shreveport, LA, ²Louisiana State University Shreveport, Shreveport, LA
Background/Purpose: This study aims to evaluate the risk of major cardiovascular events (MACE) associated with common rheumatology medications.Methods: We conducted a retrospective pharmacovigilance analysis using…
Abstract Number: 2009 • ACR Convergence 2024
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Amara Sarwal¹, Augustine Takyi¹, Guo Wei¹, McKenna Nevers¹, Ravinder Singh¹, Sydney Hartsell¹, Robert Boucher¹, Niharika Katkam¹, Akhil Chakravartula¹, Jincheng Shen¹, Srinivasan Beddhu¹ and Naomi Schlesinger², ¹University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
Abstract Number: 2631 • ACR Convergence 2024
Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
Pierre Loiseau¹, Aurélie Mailhac², Pierre Duhaut¹, Henrik Toft Sørensen² and Reimar W Thomsen², ¹Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, ²Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
May Choi¹, Hongshu Guan², Kazuki Yoshida³, Benjamin Kargere⁴, Jack Ellrodt⁵, Emma Stevens², Tianrun Cai², Brendan Everett², Brittany Weber² and Karen Costenbader⁶, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Takeda, Boston, MA, ⁴Williams College, Boston, MA, ⁵Williams College, Williamstown, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
Abstract Number: 1442 • ACR Convergence 2023
Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Renata Baronaite Hansen¹, Julia Simard², Mikkel Faurschou¹ and Søren Jacobsen³, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…
Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Hamza Liaqat¹, Muhammad Qureshi², Awais Farooq³, Mashal Awais², Amar Patel⁴ and Aisha Barlas⁵, ¹Wah Medical College, Wah Cantt, Pakistan, ²Southeast Health Internal Medicine Residency Prog., Dothan, AL, ³University of Illinois Chicago, Chicago, IL, ⁴Texas Tech University Health Sciences Center, El paso, TX, ⁵Mercy Health, Rockford, IL
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…
Abstract Number: 2384 • ACR Convergence 2023
Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group
Lisa Rosenberg¹, Larabe Farrukh¹, Simrin Kooner¹, Moiz Ehtesham¹, Sumbal Wajid¹, Ruben Peredo-Wende² and Shannon Murawski¹, ¹Albany Medical Center, Albany, NY, ²Stratton VA Medical Center, Albany, NY
Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…
Abstract Number: 0248 • ACR Convergence 2023
In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout
Panagiota Drivelegka¹, Lennart Jacobsson², Tatiana Zverkova-Sandström³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University hospital, Gothenburg, Sweden, ²University of Gothenburg, Malmö, Sweden, ³Institution of Medicine, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Patients with gout are at increased risk of acute myocardial infarction (AMI). However, the clinical course, secondary prophylaxis and mortality after AMI has not…
Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Yanint Raksadawan, Sabahat Usmani, Harigopal Sandhyavenu, Thatiana Schulze Goni, Jalpan Patel, Hafiz Muhammad Waqar Younas and Amro Taha, Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…
Abstract Number: 0447 • ACR Convergence 2022
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
Kavin Raj¹, Marlene Marte Furment², Jyoti Verma³ and Keerthana Jyotheeswara Pillai⁴, ¹University of California Riverside School of Medicine, Riverside, CA, ²SUNY Upstate University Hospital, Syracuse, NY, ³Saint Peter's University Hospital, New Brunswick, NJ, ⁴Kilpauk Medical College, Chennai, India, New Brunswick, NJ
Background/Purpose: Systemic vasculitis is a group of uncommon conditions characterized by inflammation of blood vessels, leading to organ ischemia and necrosis. Although several rheumatological disorders…
Abstract Number: 0575 • ACR Convergence 2022
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis
Leslie Spangler¹, Carrie Nielson¹, M Alan Brookhart², Rohini K Hernandez¹, Robert Kees Stad³ and Jay Lin¹, ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland
Background/Purpose: There has been inconsistent evidence published regarding the cardio- and cerebrovascular benefits and risks of anti-osteoporosis medications. EU regulators requested Amgen to evaluate the…
Abstract Number: 1195 • ACR Convergence 2022
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
Meghan Corriere, Alyson Dickson, Laura Daniel, Puran Nepal, Kathi Hall, Dale Plummer, William Dupont, Katherine Murray, Michael Stein, Wayne Ray and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1471 • ACR Convergence 2022
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
Izza Bazigh¹, Uzair Khan², Achint Patel³, Aaparna Singh³, Neha Ghalib³, Ghazi Farman⁴, Salman Muddassir³, Farrukh Zaidi⁵, Sami Mughni³ and Adam Grunbaum⁶, ¹HCA Florida Oak Hill Hospital, Spring Hill, FL, ²HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, ³HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, ⁴Rehman Medical College, Spring Hill, FL, ⁵HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, ⁶Gulf Coast Rheumatology, Trinity, FL
Background/Purpose: Cardiovascular events occur more frequently and with earlier onset in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies have concluded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].